SARS-CoV-2 Spike-pseudovirus Based Neutralization Assay

One key indicator of a vaccination or medication’s effectiveness in treating or preventing viral illnesses is its capacity to kill viruses. Normally, a live virus can be directly cultured in vitro with the vaccine or medication, and the virus’s capacity to infect cells can be seen to gauge how effective it is at neutralizing viruses. However, activities involving live viruses for the extremely contagious SARS-CoV-2 must be carried out under BSL-3 settings, which severely restricts the COVID-19 vaccine and medication development process. While pseudoviruses lack the virus’s nucleic acid and are unable to replicate within the body, they still contain the proteins required for live viruses to infect cells. As a result, they are extremely safe and adaptable, which makes them perfect instruments for researching vaccination efficacy.

The spike protein (S), membrane protein (M), envelope protein (E), and nucleocapsid protein (N) are the four structural proteins of SARS-CoV-2. S protein is one of them; it is linked to the attachment of viruses and their entry into target cells, and it is thought to be essential for initiating the infection process. Furthermore, S protein is crucial for triggering protective humoral and cellular immune responses during SASR-CoV-2 infection. Consequently, S protein has emerged as the most desirable target for the creation of medications and vaccines against SARS-CoV-2.

For every test, a fresh SARS-CoV-2 spike pseudovirus
Following incubation with the test antibody or inhibitor, ACE2-293T cells become infected by the SARS-CoV-2 Spike-pseudovirus.
To find the Luciferase luminescence value, use chemiluminescence. RLU

Based on the Luciferase luminescence value, determine the antibody or serum neutralizing inhibition rate of pseudoviruses.

Analyze how well the antibody or inhibitor to be tested neutralizes

About Author